Hummingbird, Tempus collaborate to harness AI-driven precision medicine

Uploaded By:  Paul Howell Submitted By:  Staff Reporter Case Study:  No One percent of all solid tumors harbor NRG1 fusions, a rare genetic mutation that drives malignancies. Singapore biotech company Hummingbird Bioscience has announced a collaboration with technology company Tempus to harness AI and big data in support of a biomarker-driven clinical trial for Hummingbird’s anti-HER3 antibody, HMBD-001, including those that harbor neuregulin 1 (NRG1) fusions. read more